Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Convalescent Plasma  COVID-19 treatment studies for Conv. Plasma  C19 studies: Conv. Plasma  Conv. Plasma   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Mortality 12% Improvement Relative Risk c19early.org/cp Baldeón et al. Conv. Plasma for COVID-19 RCT LATE Is late treatment with convalescent plasma beneficial for COVID-19? Double-blind RCT 158 patients in Ecuador Trial underpowered to detect differences Baldeón et al., Transfusion Medicine, doi:10.1111/tme.12851 Favors conv. plasma Favors control
Effect of convalescent plasma as complementary treatment in patients with moderate COVID-19 infection
Baldeón et al., Transfusion Medicine, doi:10.1111/tme.12851
Baldeón et al., Effect of convalescent plasma as complementary treatment in patients with moderate COVID-19 infection, Transfusion Medicine, doi:10.1111/tme.12851
Jan 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
RCT 158 patients in Ecuador, showing no significant difference in mortality with convalescent plasma. Authors note indications of improved results for earlier treatment.
risk of death, 12.0% lower, RR 0.88, p = 1.00, treatment 7 of 63 (11.1%), control 12 of 95 (12.6%), NNT 66.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Baldeón et al., 9 Jan 2022, Double Blind Randomized Controlled Trial, placebo-controlled, Ecuador, peer-reviewed, 17 authors.
Contact: mabaldeonti@uide.edu.ec.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperConv. PlasmaAll
Abstract: See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/357709366 Effect of convalescent plasma as complementary treatment in patients with moderate COVID ‐19 infection Article in Transfusion Medicine · January 2022 DOI: 10.1111/tme.12851 CITATIONS READS 5 31 17 authors, including: Manuel Baldeon Augusto Maldonado Universidad Internacional del Ecuador Universidad San Francisco de Quito (USFQ) 89 PUBLICATIONS 1,121 CITATIONS 19 PUBLICATIONS 64 CITATIONS SEE PROFILE SEE PROFILE Miguel Jacob Ochoa Andrade Francisco Xavier Mora Toro Central University of Ecuador Instituto Ecuatoriano de Seguridad Social 12 PUBLICATIONS 5 CITATIONS 11 PUBLICATIONS 66 CITATIONS SEE PROFILE Some of the authors of this publication are also working on these related projects: LMC-Helicobacter View project Chronic non-communicable diseases View project All content following this page was uploaded by Augusto Maldonado on 22 June 2022. The user has requested enhancement of the SEE PROFILE Received: 8 September 2021 Revised: 13 December 2021 Accepted: 30 December 2021 DOI: 10.1111/tme.12851 ORIGINAL ARTICLE Effect of convalescent plasma as complementary treatment in patients with moderate COVID-19 infection  n1 Manuel E. Baldeo | Augusto Maldonado2,3 | Miguel Ochoa-Andrade4 |  nica Pesantez5 | Marco Herdoiza5 | Gerardo Granja4 | Carolina Largo3 | Mo  pez3 | Marco Bonifaz4 | Hugo Espejo4 | Francisco Mora4 | Patricio Abril-Lo  nica Pacheco6 | Rafael Salazar6 | Lady Karen Robles Armijo6 | Vero Steffy Reinthaller6 | Federico Zertuche7 1 Escuela de Medicina, Facultad de Ciencias Médicas, de la Salud y de la Vida, Universidad Internacional del Ecuador, Quito, Ecuador | Marco Fornasini1 Abstract Introduction: South America is one of the regions most affected by the COVID-19 2 Escuela de Medicina, Colegio de Ciencias de la Salud, Universidad San Francisco de Quito, Quito, Ecuador n Ministerio de Salud Pública, Coordinacio Zonal 9, Hospital General Docente de n, Quito, Ecuador Caldero 3 4 Instituto Ecuatoriano de Seguridad Social, Hospital General Quito Sur - IESS, Quito, Ecuador 5 Hemocentro, Cruz Roja Ecuatoriana, Quito, Ecuador n Ministerio de Salud Pública, Coordinacio Zonal 9, Hospital Pablo Arturo Suarez, Quito, Ecuador 6 pandemic. Specific and affordable treatments are needed to treat SARS-CoV-2 infection. Evidence regarding the use of convalescent plasma in COVID-19 patients is still limited. We compared the safety and efficacy of COVID-19-convalescent plasma administration as a complement to standard treatment in the early management of patients with moderate SARS-CoV-2 infection. Methods: We carried out a random double blinded, placebo-controlled trial that compared standard treatment plus convalescent plasma (CP) or plus non-convalescent plasma in the management of COVID-19 patients. The main outcome was survival and secondary endpoints included: length of hospitalisation (LOH), days from treatment to discharge, time to clinical improvement or death within a 28-day period, and Facultad de Ciencias de la Salud Eugenio Espejo, Universidad UTE, Quito, Ecuador adverse reactions to treatment. Correspondence n, Escuela de Medicina, Manuel E. Baldeo survival, RR = 1.003, 95% CI (0.3938, 2.555). These results led to terminate the RCT pre- 7 Facultad de Ciencias Médicas, de la Salud y de la Vida, Universidad Internacional del Ecuador, n..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit